Ikena Oncology, Inc. and Inmagene Biopharmaceuticals announced the appointment of Kristin Yarema, Ph.D., as Chief Executive Officer of ImageneBio, the combined company following the anticipated merger. Dr. Yarema brings over two decades of leadership experience in human therapeutics to her new role. Her appointment is a key step in establishing the leadership for the new entity.
Dr. Yarema's background includes serving as President and CEO of Poseida Therapeutics, Inc., an oncology, autoimmune, and rare disease company, until its acquisition in January 2025. She also held significant commercial leadership positions at Atara Biotherapeutics, Inc. and Amgen, where she was Vice President and Therapeutic Area Head in Inflammation, among other roles. This experience is directly relevant to ImageneBio's new focus on immunological and inflammatory diseases.
The merger, which received shareholder approval on July 15, 2025, is expected to close by the end of July 2025, along with a concurrent $75 million private placement. Dr. Yarema expressed excitement about the opportunity to develop IMG-007, an anti-OX40 therapeutic candidate, and build value for stakeholders through execution and differentiated data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.